Humedix Co Ltd - Asset Resilience Ratio
Humedix Co Ltd (200670) has an Asset Resilience Ratio of 20.79% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Also explore Humedix Co Ltd total assets for the complete picture of this company's asset base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2015–2024)
This chart shows how Humedix Co Ltd's Asset Resilience Ratio has changed over time. See how leveraged is Humedix Co Ltd's balance sheet to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down Humedix Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see how much is Humedix Co Ltd worth.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 0% |
| Short-term Investments | ₩60.00 Billion | 20.79% |
| Total Liquid Assets | ₩60.00 Billion | 20.79% |
Asset Resilience Insights
- Good Liquidity Position: Humedix Co Ltd maintains a healthy 20.79% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company has significant short-term investments, indicating active treasury management.
Humedix Co Ltd Industry Peers by Asset Resilience Ratio
Compare Humedix Co Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK |
Drug Manufacturers - Specialty & Generic | 4.94% |
|
Jiangsu Hengrui Medicine Co Ltd
SHG:600276 |
Drug Manufacturers - Specialty & Generic | 0.16% |
|
Takeda Pharmaceutical Company Limited
F:TKDA |
Drug Manufacturers - Specialty & Generic | 0.69% |
|
Ajanta Pharma Limited
NSE:AJANTPHARM |
Drug Manufacturers - Specialty & Generic | 14.99% |
|
Kangmei Pharmaceutical Co Ltd
SHG:600518 |
Drug Manufacturers - Specialty & Generic | 0.00% |
|
Cronos Group Inc
TO:CRON |
Drug Manufacturers - Specialty & Generic | 69.94% |
|
Guizhou Bailing Group Pharmaceutical Co Ltd
SHE:002424 |
Drug Manufacturers - Specialty & Generic | 2.09% |
|
Dezhan HealthCare Co Ltd
SHE:000813 |
Drug Manufacturers - Specialty & Generic | 0.15% |
Annual Asset Resilience Ratio for Humedix Co Ltd (2015–2024)
The table below shows the annual Asset Resilience Ratio data for Humedix Co Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 31.56% | ₩78.82 Billion ≈ $53.42 Million |
₩249.75 Billion ≈ $169.25 Million |
+4.28pp |
| 2023-12-31 | 27.28% | ₩60.00 Billion ≈ $40.66 Million |
₩219.98 Billion ≈ $149.08 Million |
-7.95pp |
| 2022-12-31 | 35.23% | ₩80.01 Billion ≈ $54.22 Million |
₩227.14 Billion ≈ $153.93 Million |
+10.05pp |
| 2021-12-31 | 25.18% | ₩54.35 Billion ≈ $36.83 Million |
₩215.86 Billion ≈ $146.29 Million |
+0.33pp |
| 2020-12-31 | 24.85% | ₩43.66 Billion ≈ $29.59 Million |
₩175.65 Billion ≈ $119.03 Million |
+10.84pp |
| 2019-12-31 | 14.02% | ₩19.41 Billion ≈ $13.15 Million |
₩138.42 Billion ≈ $93.81 Million |
-9.32pp |
| 2018-12-31 | 23.34% | ₩29.94 Billion ≈ $20.29 Million |
₩128.28 Billion ≈ $86.93 Million |
-6.00pp |
| 2017-12-31 | 29.34% | ₩38.06 Billion ≈ $25.79 Million |
₩129.74 Billion ≈ $87.92 Million |
-16.31pp |
| 2016-12-31 | 45.64% | ₩59.86 Billion ≈ $40.57 Million |
₩131.16 Billion ≈ $88.88 Million |
+45.42pp |
| 2015-12-31 | 0.22% | ₩252.88 Million ≈ $171.37K |
₩115.90 Billion ≈ $78.54 Million |
-- |
About Humedix Co Ltd
Humedix Co., Ltd. engages in the manufacture and sale of various pharmaceutical products in South Korea. The company offers prescription medicines, active pharmaceutical ingredients, medical devices, cosmetics, and health functional food products. It is also involved in the manufacture and distribution of anticancer drugs. The company was formerly known as HVLS Co., Ltd. and changed its name to H… Read more